(MENAFN- PR Newswire)
OSLO, Nov. 16, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces that CMO Magnus Jäderberg will present at the NeoAg Summit 2018 (formerly Neoantigen Summit) in Boston
NeoAg Summit 2018Date: 16 November 2018 Presenter: Dr. Magnus Jäderberg, CMOPresentation time: 11:00 ETVenue: Hyatt Regency Cambridge, Boston.
Title: TG01, a neo-antigen specific vaccine targeting RAS mutations in solid tumours
Presentation slides will be available on www.targovax.com/Investors .
For further information, please contact:Renate Birkeli, Investor RelationsPhone: +47-922-61-624Email: Media and IR enquires:Andreas Tinglum - Corporate Communications (Norway)Phone: +47-9300-1773Email: Simon Conway/Stephanie Cuthbert - FTI Consulting (International)Phone: +44-20-3727-1000Email:
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/targovax/r/targovax-to-present-at-neoag-summit-2018,c2673975
SOURCE Targovax
Also from this source Nov 01, 2018, 05:45 ET Targovax ASA: Third quarter 2018 Results... Oct 26, 2018, 04:14 ET Targovax ASA: Announcement of Third Quarter 2018 Financial Results... Explore More news releases in similar topics
- All Summer Health & Safety News Releases
- All Health
- Health
- General Business
MENAFN1611201800701241ID1097704414
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.